Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood

Haematologica

Volumn 90, Issue 2, 2005, Pages 281-283

  Taube, Tillmann ^a   Schmid, Hansjörg ^b   Reinhard, Harald ^c   Von Stackelberg, Arend ^a   Henze, Günter ^a   Overberg, Ursula Schulte ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Childhood; ITP; Rituximab treatment

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB; STEROID; THROMBOCYTE ANTIBODY;

ADOLESCENT; ANTIBODY PRODUCING CELL; ARTICLE; B LYMPHOCYTE; BLEEDING; BONE MARROW BIOPSY; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; QUALITY OF LIFE; RELAPSE; REMISSION; SINGLE DRUG DOSE; SPLENECTOMY; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 14344263817     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Blanchette VS, Price V. Childhood chronic immune thrombocytopenic purpura: unresolved issues. J Pediatr Hematol Oncol 2003;Suppl 1:S28-33.
2. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9.
3. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-6.
4. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100.
5. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003; 88:538-46.
6. Braendstrup P, Pedersen M, Bjerrum OW, Nielsen OJ, Jensen BA, Nielsaage TC, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura. Blood 2003;11:[Abstract #1066].
7. Shenoy S, Kelly M, Grossman W, Ramadas J, Musselman M. Rituximab therapy in children with chronic refractory immune cytopenia: long term efficacy and immune function analysis. 2003 2003;11:[Abstract #1020].
8. Wiley JM, Wang J, Luddy RE, Bussel JB. Efficacy and safety of rituxan treatment in children with chronic immune thrombocytopenic purpura (ITP). Blood 2003;11:[Abstract #1062].
9. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141:683-8
10. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98:952-7.